Hyperlipidemia associated with protease inhibitor therapy.

Area of Science:

• Infectious Diseases
• Pharmacology
• Cardiology

Background:

• HIV infection is associated with dyslipidemia, often presenting as hypocholesterolemia and moderate hypertriglyceridemia.
• Antiretroviral therapy (ART), especially protease inhibitors (PIs), can induce or exacerbate lipid abnormalities.
• Understanding these associations is crucial for managing cardiovascular and other risks in HIV patients.

Observation:

• A case of a 35-year-old HIV-infected male is presented, who developed severe hypercholesterolemia (1472 mg/dL) and hypertriglyceridemia (8660 mg/dL) after initiating ritonavir-containing ART.
• The lipid abnormalities resolved upon ART discontinuation and lipid-lowering therapy, and did not recur when ritonavir was replaced with nelfinavir.
• This strongly suggests ritonavir as the causative agent for the extreme hyperlipidemia in this patient.

Findings:

• Protease inhibitors, notably ritonavir, are associated with hypercholesterolemia and hypertriglyceridemia, which can be extreme in some cases.
• While direct links to pancreatitis and atherosclerotic disease are not well-established for PI-induced hyperlipidemia, pancreatitis is a known complication in HIV patients.
• Protease inhibitor-induced hypertriglyceridemia may potentially contribute to pancreatitis risk.

Implications:

• The management of lipid abnormalities in HIV-infected patients on ART is complex and debated.
• Clinicians must balance the potential benefits of lipid reduction (e.g., preventing pancreatitis, atherosclerotic events) against the risks of ART intolerance, toxicity, and drug interactions.
• Individualized treatment strategies are necessary, considering patient-specific factors and potential drug-drug interactions.